Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
PCSK9 inhibitors and ACS

PCSK9 inhibitors and ACS

Evaluation of lipid management following ACS

Evaluation of lipid management following ACS

The InRange Study

The InRange Study

Clinical practice experience in patients with familial hypercholesterolemia (FH) from the SAFEHEART registry

Clinical practice experience in patients with familial hypercholesterolemia (FH) from the SAFEHEART registry

Proprotein convertase subtilisin/kexin type 9 inhibitors for heterozygous familial hypercholesterolemia: A clinical practice experience from the SAFEHEART registry

Unmet needs in adults with T2D receiving premixed insulin

Unmet needs in adults with T2D receiving premixed insulin

Patients Factors & Impacts

Patients Factors & Impacts

Myeloma Facts

Myeloma Facts

Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options

Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options

Hear from an expert on what does Dupixent bring to your practice?

Hear from an expert on what does Dupixent bring to your practice?

Expert Opinions: Would You Consider A Biologic For A CRSwnp Patient Who Has Had Sinus Surgery?

Expert Opinions: Would You Consider A Biologic For A CRSwnp Patient Who Has Had Sinus Surgery?

Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?

Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?

Time-In-Range (TIR): How to interpret it and how it is associated with outcomes

Time-In-Range (TIR): How to interpret it and how it is associated with outcomes